Diffuse Cutaneous Systemic Sclerosis
Conditions
Keywords
Diffuse Cutaneous Systemic Sclerosis (dcSSc), Diffuse Scleroderma, Diffuse Systemic Sclerosis, Scleroderma, Diffuse, Scleroderma, Progressive, Sclerosis, Progressive Systemic, Sudden Onset Scleroderma, B cell depletion, Revised Composite Response Index in Systemic Sclerosis 25 (rCRISS25), modified Rodnan skin score, forced vital capacity
Brief summary
The purpose of this study is to evaluate efficacy, safety and tolerability of s.c. ianalumab administered in participants with diffuse cutaneous systemic sclerosis relative to placebo
Detailed description
The study consists of the following periods: * Screening Period, with a duration of up to 6 weeks; * Treatment Period 1, with a duration of 52 weeks; * Treatment Period 2 (Open-label treatment), with a duration of 52 weeks; * Post-treatment Follow-up Period, with a duration of at least 20 weeks post last dose and up to 2 years.
Interventions
DRUGPlacebo
Ianalumab matching placebo subcutaneous (s.c.) injection as defined in the protocol
DRUGIanalumab
subcutaneous (s.c.) injection as defined in the protocol
Sponsors
Novartis Pharmaceuticals
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
Key Inclusion Criteria: * Male and female participants \>= 18 and =\< 70 years (at the time of the screening visit). * Diagnosis of systemic sclerosis, as defined by the 2013 American College of Rheumatology/ European League Against Rheumatism (ACR/EULAR) classification criteria for SSc (van den Hoogen et al 2013) and meet the dcSSc subset classification according to LeRoy (LeRoy 1988) * Disease duration of =\< 60 months (defined as time from the first non-Raynaud phenomenon manifestation, e.g., puffy hands, scleroderma, digital ulcers, arthralgia, dyspnea) * mRSS units of \>= 15 and =\< 45 at the time of the screening visit * Active disease that meets at least one of the following criteria at screening: * Disease duration of =\< 18 months defined as time from the first non-Raynaud phenomenon manifestation * Increase in mRSS of \>= 3 units compared with the most recent assessment performed within the previous 6 months * Involvement of one new body area and an increase in mRSS of \>= 2 units compared with the most recent assessment performed within the previous 6 months * Involvement of two new body areas within the previous 6 months * Elevated acute phase reactants (ESR) \>= 30 mm/hr or high-sensitivity C-reactive protein (hsCRP) \>= 6 mg/L) * Presence of SSc-interstitial lung disease (ILD) and ATA autoantibody positivity * Modified EUSTAR disease activity index (mDAI) ≥ 2.5 * Participant must be positive for at least one of the following autoantibodies: * anti-topoisomerase I (ATA) (also known as anti-SCL-70) * anti-RNA polymerase III (anti-RNAP3) * anti-nuclear antibody (ANA) (≥ 1:80) Participants who are positive only for ANA (while being negative for both ATA /anti-RNAP3) will be limited to 30% of the overall randomized study population. Key
Exclusion criteria
* Rheumatic disease other than dcSSc, including limited cutaneous disease (lcSSc) or sine scleroderma at the screening visit. Secondary Sjogren's disease and scleroderma myopathy are not exclusionary. * Positive anti-centromere antibody (ACA+) without positive ATA or anti-RNAP3 autoantibody result at the screening visit * Previous improvement (decrease) in mRSS \> 10 units * Pulmonary disease with FVC ≤ 50% of predicted or diffusing capacity of the lung for carbon monoxide (DLCO, corrected for hemoglobin) ≤ 40% of predicted at the screening visit * WHO Functional Class 3 or higher assessment for pulmonary arterial hypertension (PAH, as defined on right heart catheterization), receiving IV therapy for PAH or evidence of other moderately severe pulmonary disease * Participants treated with cyclophosphamide within 12 weeks prior to Baseline. * Prior use of a B-cell depleting therapy other than ianalumab (e.g., rituximab, other anti-CD20 mAb, anti-CD22 mAb, or anti-CD52 mAb) administered within 36 weeks prior to randomization, or as long as B cell count is less than the lower limit of normal or baseline value prior to receipt of B cell-depleting therapy (whichever is lower). * Treatment with biologic agents, such as intravenous immunoglobulin or monoclonal antibodies, including marketed drugs, within 12 weeks or 5 half-lives (whichever is longer) prior to baseline visit, unless explicitly allowed in inclusion criteria. * Treatment with any investigational agent within ≤ 4 weeks (or 5 half-lives of the investigational drug, whichever is longer) of the baseline visit. * Use of anti-fibrotic agents including colchicine, D-penicillamine, pirfenidone, or tyrosine kinase inhibitors (e.g., nintedanib, nilotinib, imatinib, dasatinib) in the 4 weeks prior to baseline visit. Patients with SSc-ILD requiring antifibrotics for management of ILD during the study, as per investigator judgement, should be excluded. * Previous treatment with chlorambucil, bone marrow transplantation or total lymphoid irradiation. * Women of childbearing potential, defined as all women physiologically capable of becoming pregnant from menarche until becoming post-menopausal, unless they are using highly effective methods of contraception (failure rate \< 1% per year) while taking study treatment and for 6 months after stopping study treatment. Other protocol-defined inclusion/
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| 3/5 rCRISS25 response | Week 52 | To demonstrate the superiority of ianalumab, compared to placebo, in achieving 3/5 Revised Composite Response Index in Systemic Sclerosis 25 (rCRISS25) response at Week 52 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change from baseline in FVC% predicted at Week 52 | Week 52 | To demonstrate the superiority of ianalumab, compared to placebo, on change from baseline in percent-predicted forced vital capacity (FVC%) at Week 52 |
| Change from baseline in mRSS at Week 52 | Week 52 | To demonstrate the superiority of ianalumab, compared to placebo, on change from baseline in modified Rodnan Skin Score (mRSS) at Week 52 |
| Change from baseline in HAQ-DI at Week 52 | Week 52 | To demonstrate the superiority of ianalumab, compared to placebo, on change from baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 52 |
| Ianalumab concentrations in serum during treatment and Follow-up Period | Baseline, Week 4, Week 8, Week 12, Week 24, Week 36, Week 52, Week 64, Week 76, Week 88, Week 104, Week 108, Week 112, Week 116, Week 120, Week 124 and Week 208 | To assess the pharmacokinetics of ianalumab |
| Incidence and titer of anti-drug (ianalumab) antibodies (ADAs) in serum over time | Baseline, Week 4, Week 8, Week 12, Week 24, Week 36, Week 52, Week 64, Week 76, Week 88, Week 104, Week 124, Week 208 | To evaluate the immunogenicity of ianalumab |
| Incidence and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs) | Up to Week 208 | The distribution of adverse events for ianalumab will be done via the analysis of frequencies for Adverse Event (AEs) and Serious Adverse Event (SAEs) through the monitoring of relevant clinical and laboratory safety parameters. |
Countries
Argentina, Austria, Belgium, Brazil, China, Colombia, France, Germany, Greece, Hungary, India, Italy, Japan, Malaysia, Mexico, Poland, Portugal, South Korea, Spain, Taiwan, Thailand, Turkey (Türkiye), United Kingdom, United States, Vietnam
Contacts
CONTACTNovartis Pharmaceuticals
STUDY_DIRECTORNovartis Pharmaceuticals
Novartis Pharmaceuticals
Outcome results
None listed